From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...

BIOSPAIN showed how partnering conferences connect public funding, venture capital, and pharma to drive biotech innovation to ...

Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...

Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so ...

The Asabys-Aliath integration signals how European biotech VCs are scaling and adapting amid funding pressures.

After being founded in 2017, 3T Biosciences debuted in 2022 with $40 million series A financing. As a company focused on immunotherapy, it is looking to change the future of treatment for solid tumors ...

Named after French neurologist Georges Gilles de la Tourette, who first described the disorder in 1885, Tourette’s syndrome is estimated to affect one in 10 to 1000 people worldwide. A neurological ...

One of the wealthiest countries in the world, Luxembourg is renowned for its gromperekichelcher (potato pancakes), fine wines, and medieval castles. An economic powerhouse in Europe, the country’s ...

Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals ...